High in Vitro Anti-Tumor Efficacy of Dimeric Rituximab/Saporin-S6 Immunotoxin

The anti-CD20 mAb Rituximab has revolutionized lymphoma therapy, in spite of a number of unresponsive or relapsing patients. Immunotoxins, consisting of toxins coupled to antibodies, are being investigated for their potential ability to augment Rituximab efficacy. Here, we compare the anti-tumor eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Bortolotti, Massimo, Bolognesi, Andrea, Battelli, Maria Giulia, Polito, Letizia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926157/
https://www.ncbi.nlm.nih.gov/pubmed/27338475
http://dx.doi.org/10.3390/toxins8060192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926157/
https://www.ncbi.nlm.nih.gov/pubmed/27338475
http://dx.doi.org/10.3390/toxins8060192

Ejemplares similares